Extra Corporeal Membrane Oxygenation (ECMO) Market Size, Share and Global Trend by By Modality Type (Veno-arterial (VA), Veno-venous (VV), Arterio-venous (AV)), By Indication (Respiratory Disorders, Cardiac Disorders, Extracorporeal Cardiopulmonary Resuscitation (ECPR)), By Age Group (Neonates, Pediatrics, Adults), By End-users (Hospitals, Specialty Clinics, Ambulatory Surgical Centers (ASC)) and Geography Forecast till 2022-2029

Extracorporeal membrane oxygenation (ECMO) also known as extracorporeal life support, is a technique to provide respiratory and cardiac support to patients whose lungs and heart are not capable of providing the required amount of gaseous exchange in order to sustain life. The extracorporeal membrane oxygenation device provides rest to the heart and lungs by pumping and oxygenating blood outside the patient’s body.

The veno-arterial ECMO is used in case of problems in both the heart and lungs and is connected to the artery and both the veins. The Veno-venous ECMO is used in case of the problems only in the lungs and is connected to one or more veins. According to the World Health Organisation, 17.9 million people worldwide are affected by cardiac diseases every year which accounts for 31% of the global deaths. According to the report by ExtraCorporeal Life Support Organization, in July 2018, the total number of runs performed for global extracorporeal membrane oxygenation were approximately 100,905 worldwide. 

To gain extensive insights into the market, Request for Customization

The growth in the extracorporeal membrane oxygenation market is being driven by an increase in the prevalence of cardiac and respiratory diseases, technological advancements in global extracorporeal membrane oxygenation market, and government initiatives for awareness among people. According to World Health Organization, a total number of deaths from chronic obstructive pulmonary disease (COPD) are forecasted to increase by more than 30% in the next 10 years, resulting in chronic obstructive pulmonary disease (COPD) becoming the third leading cause of death worldwide by 2030.

But, the high cost associated with the extracorporeal membrane oxygenation acts as a restraining factor for the growth of extracorporeal membrane oxygenation market.

Key Players Covered

Some of the major companies that are present in the global extracorporeal membrane oxygenation market include Maquet Holding B.V. & Co. Kg, Medtronic, Microport Scientific Corporation, Terumo Cardiovascular Systems Corporation, Medos Medizintechnik AG, Nipro Medical Corporation, Sorin Group, Ivanova PLC, Xenios AG, Getinge AB, Origen Biomedical GmbH, ALung Technologies, Inc., Euro sets, and Others. 

SEGMENTATION

According to the ExtraCorporeal Life Support Organization report in July 2018, the total number of runs for global extracorporeal membrane oxygenation in the world was 40,446 among neonates, 23,228 among Pediatrics, and 37,231 among adults, making neonates as the largest segment and is expected to continually grow during the forecast period.

Key Insights

• Prevalence of cardiac and respiratory diseases in key countries


• Technological advancements in the global extracorporeal membrane oxygenation market


• Pricing Analysis by key products


• Key mergers and acquisitions  

Regional Analysis:

Geographically, the global extracorporeal membrane oxygenation market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The global extracorporeal membrane oxygenation market dominated by North America and the region is likely to continue to dominate during the forecast year owing to the rise in lifestyle related to cardiovascular diseases. According to the American Heart Association, 1 in 7 deaths in the U.S., is due to coronary heart disease which is over 366,800 deaths each year. The Asia Pacific market is expected to register significant growth during the forecast period owing to factors like the continuously increasing population of cardiac patients, adoption of unhealthy lifestyles leading to cardiac and respiratory disorders, and increasing product penetrations of advanced extracorporeal membrane oxygenation. 

Key Industry Developments

• In October 2018, MC3 Cardiopulmonary, received U.S.FDA clearance for its CRESCENT Jugular Dual Lumen Catheter for VV-ECMO. It has a unique design that permits unmatched flow performance, minimizes recircularization, and smooth insertion.


• In September 2017, CytoSorbents Corporation announced the launch of CYTOSORB THERAPEUTIC ECMO kit to treat deadly inflammation in critically ill and cardiac surgery patients.